Biocon gains 8.5% ahead of US FDA meet to discuss breast cancer drug filing News News / News 6 years ago 492 Views comments If approved by the regulator, it will be the first Herceptin biosimilar in the US market, a development largely seen as positive for the company. Read more
News Sell OBC, Indian Cements, Kaveri Seed; buy IGL, Britannia: Sudarshan Sukhani News / News - 6 years ago
News China welcomes India, Pakistan#39;s efforts to open Kartarpur Corridor News / News - 5 years ago
Comments